Literature DB >> 24136061

Clinical presentation of Puumala virus infections in southern Austria in the peak year 2012.

E Fabian1, T Valentin, M Hoenigl, R Krause, I Zollner-Schwetz.   

Abstract

In 2012, an extraordinary rise in Puumala infections causing nephropathia epidemica (NE) was observed in southern Austria. We investigated differences in epidemiology, clinical presentation, laboratory results, treatment parameters, and outcome between patients in 2012 and previous years (2007-2011). All patients diagnosed with Puumala virus infections between 2007 and 2012 using a point of care Puumala IgM test at the microbiology laboratory, Department of Internal Medicine, Medical University of Graz, were included. In 2012, 42 and in 2007-2011 a total of 40 patients were diagnosed with NE. In 2007-2011, patients presented more frequently with arthromyalgias (25% vs 7%, p = 0.027), while lower back pain was reported more often in 2012 (21% vs 5%, p = 0.029). Other symptoms occurred at the same rate. In 2012, patients were diagnosed significantly faster (time from first contact with a physician to diagnosis 1.3 ± 0.2 vs 2.7 ± 0.4 days, p = 0.01). Significantly fewer patients required haemodialysis in 2012 (2.4% vs 20%, p = 0.01). There were no significant differences in laboratory parameters between the two groups. In the peak year 2012, patients were diagnosed faster and fewer patients required haemodialysis possibly because of the earlier diagnosis and earlier onset of therapy.

Entities:  

Mesh:

Year:  2013        PMID: 24136061     DOI: 10.1007/s10096-013-1988-4

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  14 in total

Review 1.  Clinical aspects of nephropathia epidemica (Puumala virus infection) in Europe: a review.

Authors:  B Settergren
Journal:  Scand J Infect Dis       Date:  2000

2.  Recent outbreaks of hantavirus disease in Germany and in the United States.

Authors:  Ellen Krautkrämer; Detlev H Kruger; Martin Zeier
Journal:  Kidney Int       Date:  2012-12       Impact factor: 10.612

3.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

4.  Cross-sectional survey of the seroprevalence of Puumala hantavirus in Austria.

Authors:  Wolfgang Poeppl; Selma Tobudic; Heide-Maria Winkler; Angelus Faas; Gerhard Mooseder; Heinz Burgmann
Journal:  Vector Borne Zoonotic Dis       Date:  2012-05-18       Impact factor: 2.133

5.  Viral load and humoral immune response in association with disease severity in Puumala hantavirus-infected patients--implications for treatment.

Authors:  L Pettersson; T Thunberg; J Rocklöv; J Klingström; M Evander; C Ahlm
Journal:  Clin Microbiol Infect       Date:  2013-06-07       Impact factor: 8.067

6.  Nephropathia epidemica and Puumala virus in Austria.

Authors:  S W Aberle; P Lehner; M Ecker; J H Aberle; K Arneitz; G Khanakah; A Radda; I Radda; T Popow-Kraupp; C Kunz; F X Heinz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1999-07       Impact factor: 3.267

7.  Hantavirus disease (nephropathia epidemica) in Belgium: effects of tree seed production and climate.

Authors:  K Tersago; R Verhagen; A Servais; P Heyman; G Ducoffre; H Leirs
Journal:  Epidemiol Infect       Date:  2008-07-07       Impact factor: 2.451

8.  Nephropathia epidemica in Finland: a retrospective study of 126 cases.

Authors:  J Mustonen; M Brummer-Korvenkontio; K Hedman; A Pasternack; K Pietilä; A Vaheri
Journal:  Scand J Infect Dis       Date:  1994

Review 9.  Hantavirus infections in Europe.

Authors:  Olli Vapalahti; Jukka Mustonen; Ake Lundkvist; Heikki Henttonen; Alexander Plyusnin; Antti Vaheri
Journal:  Lancet Infect Dis       Date:  2003-10       Impact factor: 25.071

10.  Evidence of disseminated intravascular coagulation in a hemorrhagic fever with renal syndrome-scoring models and severe illness.

Authors:  Erik Sundberg; Johan Hultdin; Sofie Nilsson; Clas Ahlm
Journal:  PLoS One       Date:  2011-06-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.